YU4703A - Kristalni terapeutski agens - Google Patents

Kristalni terapeutski agens

Info

Publication number
YU4703A
YU4703A YU4703A YUP4703A YU4703A YU 4703 A YU4703 A YU 4703A YU 4703 A YU4703 A YU 4703A YU P4703 A YUP4703 A YU P4703A YU 4703 A YU4703 A YU 4703A
Authority
YU
Yugoslavia
Prior art keywords
cristalline
therapeutic agent
pyridylsulfonylc
ethylpiperazine
polymorph
Prior art date
Application number
YU4703A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU4703A publication Critical patent/YU4703A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
YU4703A 2000-07-28 2001-07-18 Kristalni terapeutski agens YU4703A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
YU4703A true YU4703A (sh) 2006-01-16

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
YU4703A YU4703A (sh) 2000-07-28 2001-07-18 Kristalni terapeutski agens

Country Status (45)

Country Link
EP (1) EP1305314B1 (enExample)
JP (1) JP2004505087A (enExample)
KR (1) KR100457937B1 (enExample)
CN (1) CN1207297C (enExample)
AP (1) AP1400A (enExample)
AR (1) AR032628A1 (enExample)
AT (1) ATE286901T1 (enExample)
AU (2) AU2001272690B2 (enExample)
BG (1) BG107266A (enExample)
BR (1) BR0112734A (enExample)
CA (1) CA2417264C (enExample)
CZ (1) CZ2003126A3 (enExample)
DE (1) DE60108398T2 (enExample)
DO (1) DOP2001000217A (enExample)
DZ (1) DZ3364A1 (enExample)
EA (1) EA004681B1 (enExample)
EC (1) ECSP034454A (enExample)
EE (1) EE200300045A (enExample)
ES (1) ES2231521T3 (enExample)
GE (1) GEP20053494B (enExample)
HR (1) HRP20030061A2 (enExample)
HU (1) HUP0302982A3 (enExample)
IL (1) IL153226A0 (enExample)
IN (1) IN2002MU01649A (enExample)
IS (1) IS6626A (enExample)
MA (1) MA26931A1 (enExample)
MX (1) MX233602B (enExample)
MY (1) MY117831A (enExample)
NO (1) NO324220B1 (enExample)
NZ (1) NZ523226A (enExample)
OA (1) OA12337A (enExample)
PA (1) PA8523501A1 (enExample)
PE (1) PE20020277A1 (enExample)
PH (1) PH12001001922B1 (enExample)
PL (1) PL365133A1 (enExample)
PT (1) PT1305314E (enExample)
SK (1) SK572003A3 (enExample)
SV (1) SV2001000570A (enExample)
TN (1) TNSN01112A1 (enExample)
TW (1) TWI285643B (enExample)
UA (1) UA72631C2 (enExample)
UY (1) UY26854A1 (enExample)
WO (1) WO2002010171A1 (enExample)
YU (1) YU4703A (enExample)
ZA (1) ZA200301457B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371647B1 (en) * 1998-04-20 2005-07-13 Pfizer Inc. Pyridine-3-carboxylic acid derivatives and their use as intermediates
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
AU7269001A (en) 2002-02-13
DE60108398T2 (de) 2005-12-22
MX233602B (es) 2006-01-10
OA12337A (en) 2006-05-15
MA26931A1 (fr) 2004-12-20
MY117831A (en) 2004-08-30
PL365133A1 (en) 2004-12-27
IL153226A0 (en) 2003-07-06
HRP20030061A2 (en) 2003-04-30
MXPA03000856A (es) 2003-06-06
KR100457937B1 (ko) 2004-11-20
AR032628A1 (es) 2003-11-19
BG107266A (bg) 2003-07-31
TWI285643B (en) 2007-08-21
ES2231521T3 (es) 2005-05-16
NZ523226A (en) 2003-07-25
HUP0302982A3 (en) 2005-01-28
DOP2001000217A (es) 2002-10-30
NO324220B1 (no) 2007-09-10
UA72631C2 (uk) 2005-03-15
KR20030016430A (ko) 2003-02-26
EE200300045A (et) 2004-12-15
CZ2003126A3 (cs) 2004-02-18
IN2002MU01649A (enExample) 2004-12-11
PH12001001922B1 (en) 2006-11-21
UY26854A1 (es) 2002-02-28
AP1400A (en) 2005-04-28
JP2004505087A (ja) 2004-02-19
DE60108398D1 (de) 2005-02-17
HUP0302982A2 (hu) 2003-12-29
EP1305314B1 (en) 2005-01-12
EP1305314A1 (en) 2003-05-02
WO2002010171A1 (en) 2002-02-07
ECSP034454A (es) 2003-03-10
EA200300079A1 (ru) 2003-06-26
SV2001000570A (es) 2002-09-03
CN1207297C (zh) 2005-06-22
GEP20053494B (en) 2005-04-25
AU2001272690B2 (en) 2005-12-08
BR0112734A (pt) 2004-08-10
EA004681B1 (ru) 2004-06-24
SK572003A3 (en) 2004-05-04
NO20030416D0 (no) 2003-01-27
DZ3364A1 (fr) 2002-02-07
NO20030416L (no) 2003-02-05
IS6626A (is) 2002-11-18
HK1055954A1 (en) 2004-01-30
PT1305314E (pt) 2005-04-29
AP2001002234A0 (en) 2001-09-30
PA8523501A1 (es) 2002-10-24
CN1444585A (zh) 2003-09-24
PE20020277A1 (es) 2002-05-11
ATE286901T1 (de) 2005-01-15
TNSN01112A1 (fr) 2005-11-10
CA2417264C (en) 2007-06-12
ZA200301457B (en) 2004-04-28
CA2417264A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
HUP0301651A2 (en) Indolylmaleimide derivatives, pharmaceutical compositions containing them, process for producing them and their use
MY132106A (en) New pyridazin-3(2h)-one derivatives
IL153508A0 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
HRP20020798A2 (en) 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS
HRP20020198B1 (hr) Formulacija moksifloksacina i kuhinjske soli
HK1046527A1 (zh) 金剛烷衍生物
SG146442A1 (en) Sulphonamide derivatives, their preparation and use as medicaments
HUP0400195A3 (en) Imidazole derivatives for modulatig sodium channels, pharmaceutical compositions containing them and use of imidazole derivatives for producing pharmaceutical compositions having sodium channels modulating effect
HUP0402489A3 (en) 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
WO2001016136A3 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
MXPA03010761A (es) Combinaciones farmaceuticas.
AU2001273384A1 (en) 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
BG106930A (en) Substituted phenyl-piperazine derivatives, their preparation and use
AU3657100A (en) Use of water-soluble beta-(1,3) glucans as agents for producing therapeutic skintreatment agents
IL159570A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
HUT74948A (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
PL348935A1 (en) Method fo obtaining compounds of pyrazole [4,3-d]pyrimidin-7-one type and intermediate products
AP1400A (en) Crystalline therapeutic agent.
IL162524A0 (en) Derivatives of (pyridin-3-yl)-1-azabicycloÄ3.2.1Ü octane, their preparation and their terapeutic application
PL329596A1 (en) Novel sulphonamide-type compounds, their application in production of pharmaceutic agents and pharmaceutic agent as such
PY0117546A (es) Agente terapeutico cristalino